Crescent Biopharma, Inc. (CBIO) Stock Grade

About Crescent Biopharma, Inc.'s fundamentals

Crescent Biopharma is a biotechnology company with a market capitalization of $539.7 million that reported zero revenue growth year-over-year, indicating stagnant or flat sales. The company posted a significant net loss in its latest annual statement, reflected in its -1419.6% net margin, meaning it is currently unprofitable and spending substantially more than it generates in revenue. With no dividend yield and negative profitability metrics, the company is in a pre-revenue or early-stage development phase typical of many biotechnology firms focused on research and development rather than near-term earnings.